Correlation Between Samsung Biologics and OLIPASS

Can any of the company-specific risk be diversified away by investing in both Samsung Biologics and OLIPASS at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Samsung Biologics and OLIPASS into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Samsung Biologics Co and OLIPASS, you can compare the effects of market volatilities on Samsung Biologics and OLIPASS and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Samsung Biologics with a short position of OLIPASS. Check out your portfolio center. Please also check ongoing floating volatility patterns of Samsung Biologics and OLIPASS.

Diversification Opportunities for Samsung Biologics and OLIPASS

0.4

Correlation Coefficient

Samsung Biologics  OLIPASS

Very weak diversification

The 3 months correlation between Samsung and OLIPASS is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Samsung Biologics Co and OLIPASS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OLIPASS and Samsung Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Samsung Biologics Co are associated (or correlated) with OLIPASS. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OLIPASS has no effect on the direction of Samsung Biologics i.e., Samsung Biologics and OLIPASS go up and down completely randomly.

Pair Corralation between Samsung Biologics and OLIPASS

Assuming the 90 days trading horizon Samsung Biologics Co is expected to under-perform the OLIPASS. But the stock apears to be less risky and, when comparing its historical volatility, Samsung Biologics Co is 3.25 times less risky than OLIPASS. The stock trades about -0.08 of its potential returns per unit of risk. The OLIPASS is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  499,500  in OLIPASS on October 6, 2024 and sell it today you would lose (22,500) from holding OLIPASS or give up 4.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Samsung Biologics Co  vs.  OLIPASS

Samsung Biologics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Samsung Biologics Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Samsung Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

OLIPASS

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in OLIPASS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, OLIPASS may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Samsung Biologics and OLIPASS

The main advantage of trading using opposite Samsung Biologics and OLIPASS positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Samsung Biologics position performs unexpectedly, OLIPASS can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OLIPASS will offset losses from the drop in OLIPASS's long position.

The idea behind Samsung Biologics Co and OLIPASS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.